1 / 12

Problematic and injecting drug use – findings from the Harm Reduction Database (HRD)

Problematic and injecting drug use – findings from the Harm Reduction Database (HRD). Presenter: Josie Smith, Health Protection, PHW. Estimates of problematic and injecting drug use. EMCDDA

roanna-abbott
Télécharger la présentation

Problematic and injecting drug use – findings from the Harm Reduction Database (HRD)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Problematic and injecting drug use – findings from the Harm Reduction Database (HRD) Presenter: Josie Smith, Health Protection, PHW

  2. Estimates of problematic and injecting drug use EMCDDA • Problematic drug use – “injecting drug use or long duration or regular use of opioids, cocaine and/or amphetamines” • UK estimates indicate around 1% or 10 per 1000 population aged 15 – 64 years • Translates to around 20,000 individuals in Wales • Injecting drug use – UK estimates indicate around 0.4% of population aged 15 – 64 years • Translates to around 8,000 individuals in Wales

  3. Wales HRD data 1/09/10 – 31/03/11 7277 individuals registered with needle exchange • Female – 1004 (14%) • Male – 6273 (86%) Would expect: 25% female 75% male Pharmacy? • What is the extent of secondary / peer distribution?

  4. Profile of service provision 2011

  5. Number of individuals registered

  6. Wales data – Age profile by genderData from all sites: Activity 01/09/10 to 31/03/11

  7. Profile of substances used by APB

  8. Details available for analysis • Age • Gender • Year of first injecting • Area of residence • Housing status • Substances used • Blood borne virus monitoring • Injecting equipment reuse and sharing behaviour

  9. Uses of data / reporting mechanisms • Provider activity data • Planning of opening times, additional services for young people, females, steroid users • Address additional health / other needs • Address specific risk behaviours with service users • Local planning (APB/CSP/SMARTs) • Coverage • Quality • Nature of local injecting (and wider problematic drug use) behaviours • National planning (WAG, Public Health)

  10. Next steps: Improving data quality • Some services completing client details • Other services completing bare minimum - visits to sites reinforcing need to complete client details/assessment in order to provide quality service

  11. Next steps : rolling out to pharmacy • Working in conjunction with Pharmacy WAG to implement in existing community pharmacy services across Wales (2011) • Addition of take home Naloxone section – stat and voluntary sector

  12. All service users and staff from voluntary and statutory services Regional co-ordinators WAG Public Health Thank you!

More Related